

Oral Biologics & Biosimilars Global Market To Grow At Rate Of 16% Through 2026

The Business Research Company's Oral Biologics & Biosimilars Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON , UK,
September 2, 2022 /EINPresswire.com/
-- According to 'Oral Biologics & Biosimilars Global Market Report 2022 – Market Size, Trends, And Global

Forecast 2022-2026' published by The Business Research Company, the oral biologics & biosimilars market share is expected to grow to \$9.44 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to propel the oral biologics & biosimilars industry growth.

Want to learn more on the oral biologics & biosimilars market growth? Request for a Sample now.

<https://www.thebusinessresearchcompany.com/sample.aspx?id=6830&type=smp>

The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services by entities (organizations, sole traders, partnership) used to treat chronic diseases such as diabetes, arthritis, and cancer. Biologics are drugs made from living cells using highly complex technology, while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer the same active properties as any licensed biological drug. The oral biologics and biosimilar market comprise biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS, and other serious conditions.

[Global Oral Biologics & Biosimilars Market Trends](#)

The creation of new insulin biosimilar is one of the key oral biologics & biosimilars market trends gaining popularity. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin to capture the market share. For instance, in 2019, Mylan, a US-based pharmaceutical company, in partnership with Biocon, launched a biosimilar insulin glargine named Semglee in Australia. Biocon is an Indian-based



The Business
Research Company

Oral Biologics & Biosimilars Market Report 2022 –
Market Size, Trends, And Global Forecast 2022-2026

biopharmaceutical company. Also in 2019, Oramed Pharmaceuticals, a Jerusalem-based pharmaceutical company, developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

Global Oral Biologics & Biosimilars Market Segments

The global oral biologics & biosimilars market is segmented:

By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, and Tumor Necrosis Factor-Alpha Inhibitors

By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others

By Molecule Type: Vaccines, Proteins and Peptides, Monoclonal Antibodies, and Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Geography: The global oral biologics & biosimilars market analysis report is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America accounts for the largest share.

Read more on the global oral biologics & biosimilars market report here

<https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-global-market-report>

Oral Biologics & Biosimilars Global Market Report 2022 is one of a series of new reports from The Business Research Company that provides oral biologics & biosimilars global market overviews, analyzes and forecasts market size and growth for the global oral biologics & biosimilars market, oral biologics & biosimilars global market share, oral biologics & biosimilars market segments and geographies, oral biologics & biosimilars global market players, oral biologics & biosimilars global market leading competitor revenues, profiles and market shares. The oral biologics & biosimilars global market report identifies top countries and segments for opportunities and strategies based on market trends and key competitors' approaches.

TBRC's Oral Biologics & Biosimilars Global Market Report 2022 includes information on the following:

Data Segmentations: Market Size, Global, By Region and Country, Historic and Forecast, and Growth Rates for 60 Geographies

Key Market Players: Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, and Emisphere Technologies.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

And so much more.

Looking for something else? Here is a list of similar reports by The Business Research Company:

Kidney Cancer Drugs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report>

Biologics Market 2022

<https://www.thebusinessresearchcompany.com/report/biologics-market>

Interleukin Inhibitors Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/interleukin-inhibitor-global-market-report>

[About The Business Research Company](#)

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Contact Information:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

TBRC Blog: <http://blog.tbrc.info/>

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Twitter: https://twitter.com/tbrc_info

Facebook: <https://www.facebook.com/TheBusinessResearchCompany>

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/589021345>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.